CRO Albany Molecular Research has announced Thomas E. D'Ambra, Ph.D., will retire as president and chief executive officer, effective Dec. 31. D'Ambra will be named non-executive chairman of the board of directors on the same date.
D'Ambra will be succeeded as by William S. Marth, currently non-executive chairman of the AMRI board, effective Jan. 1. Marth will remain a board member.
Marth joined AMRI’s board in June 2012. Formerly he was president and chief executive officer of Teva Americas, retiring from Teva in 2012. He is a senior advisor to Teva through the end of 2013. He was president and CEO of Teva North America from 2008 to 2010, president and CEO of Teva U.S. and executive vice president and vice president of sales and marketing for Teva U.S.
Marth led the respiratory, neuroscience, oncology and women's healthcare divisions, as well as Latin America and Canada. He was a member of Teva's global executive management team and Teva Americas' board from 2007 until 2013. He brings global experience in strategic planning, investor relations, R&D, supply chain and regulatory. He was the architect of the $6.8 billion Cephalon and$7.4 billion Barr Laboratories acquisitions. Previously, he held various positions with the Apothecon division of Bristol-Myers Squibb.
Marth was chairman of the board of the Generic Pharmaceutical Association (GPhA) in 2008 and 2009 and the American Society for Health-System Pharmacists (ASHP) in 2010.